Exarafenib

Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].

Product Specifications

CAS Number

[2639957-39-2]

Product Name Alternative

RAF/KIN_2787

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P38 MAPK; Raf

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/exarafenib.html

Purity

99.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=CC=C(NC(N2C[C@@H](CC2)CC(F)(F)F)=O)C=C1C3=CC(N[C@H](C)CO)=NC(N4CCOCC4)=C3

Molecular Formula

C26H34F3N5O3

Molecular Weight

521.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Miller N, et, al. Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in combination with MEK inhibition in preclinical models of human NRAS mutant melanoma.2022 Jun 2;40 (16) : e15099.|[2]WHO Drug Information. International Nonproprietary Names for Pharmaceutical